SBBP News and Press, Strongbridge Biopharma plc From 02/25/21

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...

Strongbridge Biopharma (SBBP) is up ~25.0% in above-average volume after the company announced the promotion of Richard S. Kollender to the position of president and chief financial officer with effect from March 3, 2021.Previously served as the chief operating officer of Stron...

Socket Mobile (SCKT) +181% after launching first enterprise-grade scanners for Apple iPhone 12 series.ALJ Regional Holdings (ALJJ) +71%.500.com Limited (WBAI) +74% after acquisition of crypto mining pool.Urban Tea, Inc. (MYT) +55%.Torchlight Energy Resources, Inc. (TRCH)&#...

DUBLIN, Ireland and TREVOSE, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

Strongbridge Biopharma is looking at a major inflection year in 2021. In early January, the company provided strong preliminary fourth-quarter guidance but the major catalyst this year is the potential FDA approval of RECORLEV. We size up this small cap biopharma's prospects this ...

Strongbridge Biopharma (SBBP) sees Q4 Keveyis (dichlorphenamide) net product sales of ~$8.2M, consensus of $7.05M.FY 2020 Keveyis revenue is expected to be ~$30.7M, exceeding projections of $28M - $29M, and well ahead of consensus $29.44M.FY 2021 Keveyis revenue outlook of ~$34M to ...

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~ ~ Targets Full-Year 2021 KEVEYIS ® ...

DUBLIN, Ireland and TREVOSE, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential catalysts on the horizon in 2021. We revisit this $2.50 biopharma name and updat...